natgillin/translations-raw huggingface dataset:
A test set contains 50 jars with the additional components:
Test vsebuje 50 lončkov z dodatnimi sestavinami:
A test set contains 50 jars with the additional components:
Testni komplet vsebuje 50 lončkov skupaj z dodatnimi sestavinami:
A test set contains the following parts:
Testni komplet vsebuje naslednje sestavine:
A test to determine your liver function will be performed before the start of Eucreas treatment, at three-month intervals for the first year and periodically thereafter.
Pred začetkom zdravljenja z zdravilom Eucreas boste opravili preiskavo delovanja jeter, med zdravljenjem pa boste v prvem letu opravljali kontrolne preiskave na tri mesece in kasneje v rednih časovnih intervalih.
A test to determine your liver function will be performed before the start of Jalra treatment, at three- month intervals for the first year and periodically thereafter.
Pred začetkom zdravljenja z zdravilom Jalra boste opravili preiskavo delovanja jeter, med zdravljenjem pa boste v prvem letu opravljali kontrolne preiskave na tri mesece in kasneje v rednih časovnih intervalih.
A test to determine your liver function will be performed before the start of Xiliarx treatment, at three-month intervals for the first year and periodically thereafter.
Pred začetkom zdravljenja z zdravilom Xiliarx boste opravili preiskavo delovanja jeter, med zdravljenjem pa boste v prvem letu opravljali kontrolne preiskave na tri mesece in kasneje v rednih časovnih intervalih.
a Thalidomide dosed once daily at bedtime on Days 1 to 42 of each 42-day cycle. b Due to the sedative effect associated with thalidomide, administration at bedtime is known to generally improve tolerability. c Melphalan dosed once daily on Days 1 to 4 of each 42-day cycle. d Melphalan dosing: reduce by 50% for moderate (creatinine clearance: ≥30 but <50 mL/min) or severe (CrCl: <30mL/min) renal insufficiency e Maximum daily melphalan dose: 24 mg (subjects ≤75 years old) or 20 mg (subjects >75 years old). f Prednisone dosed once daily on Days 1 to 4 of each 42-day cycle.
a Talidomid se daje enkrat na dan pred spanjem od 1. do 42. dne vsakega 42-dnevnega cikla. b Znano je, da zaradi sedativnega učinka, povezanega s talidomidom, dajanje pred spanjem na splošno izboljša prenašanje. c Melfalan se daje enkrat na dan od 1. do 4. dne vsakega 42-dnevnega cikla. d Odmerjanje melfalana: zmanjšajte odmerek za 50 % pri zmerni (očistek kreatinina: ≥30, vendar <50 ml/min) ali hudi (CrCl: <30ml/min) insuficienci ledvic. e Največji dnevni odmerek melfalana: 24 mg (osebe, stare ≤75 let) ali 20 mg (osebe, stare >75). f Prednizon se daje enkrat na dan od 1. do 4. dne vsakega 42-dnevnega cikla.
a The difference in proportions and its 95% CIs between randomised treatment groups is based on normal approximation.
a Razlika v deležih in njihovi 95-odstotni IZ med randomiziranimi skupinami zdravljenja temelji na normalnem približevanju.
a The first dose should be given at 2 months of age.
a Prvi odmerek je treba dati pri starosti 2 mesecev.
a The following ADRs are not listed but also calculated in the frequency for Local reactions: feeling hot, infusion site paresthesia. b Gravitational oedema/genital swelling was observed subsequent to lower abdominal quadrants administration.
a Naslednji neželeni učinki niso navedeni, a so upoštevani pri pogostnosti lokalnih reakcij: občutek vročine, parestezija na mestu infundiranja. b Po infundiranju v spodnja trebušna kvadranta so opazili gravitacijski edem/otekanje genitalij.
a The population used for analysis of histology included only patients with available liver biopsy data (Missing = Excluded) by week 240.
a V populaciji, ki so jo uporabili za histološko analizo, so bili samo bolniki, za katere so bili na voljo podatki o biopsiji jeter (manjkajoči = izključeni) do 240. tedna.
a The recurrence rate is the Kaplan-Meier (KM) estimate at the target study date of the visit expressed as a percentage (95% CI).
a Stopnja ponovitve je ocena po Kaplan–Meier (KM), opravljena ob ciljnem datumu obiska za namene študije in izražena v odstotkih (95-odstotni interval zaupanja).
a The safety profile from MEK116513 is generally similar to that of MEK115306 with the following exceptions:
a Varnostni profil v študiji MEK116513 je bil večinoma podoben kot v študiji MEK115306 z naslednjimi izjemami: 1.
a The term cough includes the following terms: cough, productive cough, and upper airway cough syndrome. b The term lymphopenia includes the following terms: lymphopenia and lymphocyte count decreased. c The term pneumonia is a grouping of the following terms: pneumonia, atypical pneumonia, bronchopneumonia, lobar pneumonia, bacterial pneumonia, fungal pneumonia, pneumonia influenza, and pneumococcal pneumonia. d The term herpes zoster is a grouping of the following terms: herpes zoster, oral herpes, and herpes virus infection.
a Izraz kašelj vključuje naslednje izraze: kašelj, produktivni kašelj in sidrom kašlja zgornjih dihalnih poti. b Izraz limfopenija vključuje naslednje izraze: limfopenija in zmanjšanje števila limfocitov. c Izraz pljučnica je skupina naslednjih izrazov: pljučnica, atipična pljučnica, bronhopnevmonija, lobarna pljučnica, bakterijska pljučnica, glivična pljučnica, virusna pljučnica in pnevmokokna pljučnica. d Izraz herpes zoster je skupina naslednjih izrazov: herpes zoster, oralni herpes in herpesvirusna okužba.
a The term herpes zoster is a grouping of the following terms: herpes zoster, oral herpes, and herpes virus infection. b The term pneumonia is a grouping of the following terms: pneumonia, atypical pneumonia, bronchopneumonia, lobar pneumonia, bacterial pneumonia, fungal pneumonia, pneumonia influenza, and pneumococcal pneumonia. c The term lymphopenia includes the following terms: lymphopenia and lymphocyte count decreased. d The term cough includes the following terms: cough, productive cough, and upper airway cough syndrome.
a Izraz herpes zoster je skupina naslednjih izrazov: herpes zoster, oralni herpes in herpesvirusna okužba. b Izraz pljučnica je skupina naslednjih izrazov: pljučnica, atipična pljučnica, bronhopnevmonija, lobarna pljučnica, bakterijska pljučnica, glivična pljučnica, virusna pljučnica in pnevmokokna pljučnica. c Izraz limfopenija vključuje naslednje izraze: limfopenija in zmanjšanje števila limfocitov. d Izraz kašelj vključuje naslednje izraze: kašelj, produktivni kašelj in sidrom kašlja zgornjih dihalnih poti.
a The total dose per cycle was 100 mg/m2
a celotni odmerek na krog zdravljenja je znašal 100 mg/m2
a The white to off-white cake will dissolve completely.
Bela do skoraj bela pogača se bo povsem raztopila.
A therapeutic dose of 9 mcg/day or 28 mcg/day should be administered to the patient by infusing a total of 240 mL BLINCYTO solution for infusion at one of 4 constant infusion rate and associated infusion durations:
Terapevtski odmerek 9 mcg/dan ali 28 mcg/dan je treba bolniku dati z infundiranjem skupno 240 ml BLINCYTO raztopine za infundiranje z 1 od 4 stalnih hitrosti infundiranja in ustreznim trajanjem infundiranja:
A therapeutic dose of 9 mcg/day or 28 mcg/day should be administered to the patient by infusing a total of 240 mL BLINCYTO solution for infusion at one of 4 constant infusion rates and associated infusion durations:
Terapevtski odmerek 9 mcg/dan ali 28 mcg/dan je treba bolniku dati z infundiranjem skupne količine 240 ml raztopine za infundiranje BLINCYTO z 1 od 4 stalnih hitrosti infundiranja in ustreznim trajanjem infundiranja:
A therapy session can be administered for single or multiple lesions or entire treatment fields.
V okviru enega zdravljenja se lahko zdravi ena ali več lezij hkrati ali celotno polje zdravljenja.
a These adverse reactions were identified through post-marketing surveillance, however, the frequencies were estimated from a statistical calculation based on the total number of patients exposed to REYATAZ in randomised controlled and other available clinical trials (n = 2321). b See description of selected adverse reactions for more details.
a O teh neželenih učinkih so poročali med spremljanjem zdravila po pridobitvi dovoljenja za promet, pogostnosti pa so bile ocenjene s pomočjo statističnega izračuna na osnovi skupnega števila bolnikov, ki so se z zdravilom REYATAZ zdravili v randomiziranih nadzorovanih in drugih izvedenih kliničnih preskušanjih (n = 2.321). b Za več podrobnosti glejte Opis izbranih neželenih učinkov v nadaljevanju.
a These adverse reactions were identified through post-marketing surveillance; however, the frequencies were estimated from a statistical calculation based on the total number of patients exposed to atazanavir (with and without ritonavir) in randomised controlled and other available clinical trials (n = 2321). b See section Description of selected adverse reactions for more details.
a Te neželene učinke so odkrili med spremljanjem zdravil po prihodu na trg, njihova pogostnost pa je ocenjena s pomočjo statističnega izračuna na podlagi celotnega števila bolnikov, ki so bili izpostavljeni atazanavirju (z ritonavirjem ali brez njega) v randomiziranih nadzorovanih ali drugih razpoložljivih kliničnih preskušanjih (n = 2.321). b Za podrobnosti glejte Opis izbranih neželenih učinkov.
a These criteria meet the National Cancer Institute Common Toxicity Criteria (CTC v2.0; NCI 1998) definition of ≥ CTC Grade 2 bleeding
aTa merila ustrezajo Merilom pogostih toksičnosti Nacionalnega inštituta za rakava obolenja (National Cancer Institute Common Toxicity Criteria, CTC v2.0; NCI 1998), definiciji za  CTC stopnjo krvavitve 2
a These criteria meet the National Cancer Institute Common Toxicity Criteria (CTC v2.0; NCI 1998) definition of ≥ CTC Grade 2 bleeding
aTa merila ustrezajo Merilom pogostih toksičnosti Nacionalnega inštituta za rakava obolenja (National Cancer Institute Common Toxicity Criteria, CTC v2.0; NCI 1998), definiciji za  CTC stopnjo krvavitve 2.
a These criteria meet the National Cancer Institute Common Toxicity Criteria (CTC v2.0; NCI 1998) definition of ≥ CTC Grade 2 bleeding.
a Ta merila ustrezajo Merilom pogostih toksičnosti Nacionalnega inštituta za rakava obolenja (National Cancer Institute Common Toxicity Criteria, CTC v2.0; NCI 1998), definiciji za ≥ CTC stopnjo krvavitve 2
a These criteria meet the National Cancer Institute Common Toxicity Criteria (CTC v2.0; NCI 1998) definition of ≥CTC Grade 2 bleeding
aTa merila ustrezajo Merilom pogostih toksičnosti Nacionalnega inštituta za rakava obolenja (National Cancer Institute Common Toxicity Criteria, CTC v2.0; NCI 1998), definiciji za  CTC stopnjo krvavitve 2
a These criteria meet the National Cancer Institute Common Toxicity Criteria (CTC v2.0; NCI 1998) definition of ≥CTC Grade 2 bleeding
aTa merila ustrezajo Merilom pogostih toksičnosti Nacionalnega inštituta za rakava obolenja (National Cancer Institute Common Toxicity Criteria, CTC v2.0; NCI 1998), definiciji za  CTC stopnjo krvavitve 2.
a These criteria meet the National Cancer Institute Common Toxicity Criteria (CTC v2.0; NCI 1998) definition of ≥CTC Grade 2 bleeding.
a Ta merila ustrezajo Merilom pogostih toksičnosti Nacionalnega inštituta za rakava obolenja (National Cancer Institute Common Toxicity Criteria, CTC v2.0; NCI 1998), definiciji za ≥ CTC stopnjo krvavitve 2.
a These criteria meet the National Cancer Institute Common Toxicity Criteria (CTC v2.0; NCI 1998) definition of ≥CTC Grade 2 bleeding.
aTa merila ustrezajo Merilom pogostih toksičnosti Nacionalnega inštituta za rakava obolenja (National Cancer Institute Common Toxicity Criteria, CTC v2.0; NCI 1998), definiciji za  CTC stopnjo krvavitve 2
a thiazolidinedione, when the thiazolidinedione alone with diet and exercise, does not provide adequate glycaemic control in patients for whom use of a thiazolidinedione is considered appropriate.
tiazolidindionom, kadar tiazolidindion sam, z dieto in telesno dejavnostjo ne zagotovi ustrezne urejenosti glikemije, uporaba tiazolidindionov pa je za bolnika primerna.
A thin layer of small bubbles may remain at the top of the solution in the syringe.
Na površini raztopine v brizgi sme ostati tenka plast majhnih mehurčkov.
A thin layer of the cream should be applied to clean and dry affected areas.
Tanek sloj kreme je treba nanesti na čisto in suho kožo prizadetih predelov.
A thin layer of the powder can be applied directly from the vial or using a spray device directly onto the bleeding surface, followed by application of the gelatin sponge.
Tanka plast praška se lahko nanese neposredno iz viale ali z uporabo pršilnika neposredno na površino krvavitve, nato pa se nanjo položi želatinska gobica.
A third (booster) dose of H5N1 vaccine combined with MF59C was administered 6 months onwards after the primary vaccination series.
Tretji (obnovitveni) odmerek cepiva proti H5N1 z dodanim MF59C je bil dan po 6 ali več mesecih po primarnem cepljenju.
A third dose is recommended in the second year of life.
Cepljenje s tretjim odmerkom je priporočljivo v drugem letu življenja.
A third functional binding site in the Fc-region of catumaxomab enables interaction with accessory immune cells via Fc receptors.
Tretja površina funkcionalne vezave na območju Fc katumaksomaba omogoča medsebojno delovanje z dodatnimi imunskimi celicami prek receptorjev Fc.
A third group of 110 patients received bolus 5-FU/FA
Tretja skupina 110 bolnikov je prejela bolus
A third injection (booster) will be given after an interval of 12 to 23 months from the second injection.
Tretja injekcija (poživitveni odmerek) se daje od 12 do 23 mesecev po drugi injekciji.
A third injection (booster) will be given in the second year of life after an interval of at least 2 months from the second injection.
Tretja injekcija (poživitveni odmerek) se daje v drugem letu življenja s presledkom vsaj 2 mesecev po drugi injekciji.
A third injection will be given in the second year of life with at least two months apart.
Tretji odmerek otrok dobi v drugem letu življenja in s presledkom vsaj 2 meseca.
A third main study compared Pradaxa (110 mg and 150 mg twice a day) with warfarin (another anticoagulant) in around 18,000 adult patients with non-valvular atrial fibrillation who were considered to be at risk of stroke.
V tretji glavni študiji so zdravilo Pradaxa (110 mg in 150 mg dvakrat dnevno) primerjali z varfarinom (drugim antikoagulantom) pri okrog 18 000 odraslih bolnikih z atrijsko fibrilacijo brez okvare srčnih zaklopk, pri katerih je obstajalo tveganje za nastanek kapi.
A third study compared Edistride with a sulphonylurea (glipizide), both taken in combination with metformin in 814 patients.
V tretji študiji, v katero je bilo vključenih 814 bolnikov, so zdravilo Edistride primerjali s sulfonilsečnino (glipizidom), pri čemer sta se obe zdravili dajali skupaj z metforminom.
A third study compared Forxiga with a sulphonylurea (glipizide), both taken in combination with metformin in 814 patients.
Tretja študija je zdravilo Forxiga primerjala s sulfonilsečnino (glipizidom), pri čemer je 814 bolnikov prejemalo obe učinkovini v kombinaciji z metforminom.
A third study in 776 children compared the effects of M-M-RVAXPRO when given as injected into the muscle and when injected under the skin.
V tretji študiji s 776 otroki so primerjali učinke cepiva M-M-RVAXPRO, če je injicirano v mišico ali če je injicirano pod kožo.
A third study investigated the effectiveness of Kalydeco in patients with cystic fibrosis due to several mutations other than G551D.
V drugi študiji so proučevali učinkovitost zdravila Kalydeco pri bolnikih s cistično fibrozo zaradi drugih oblik mutacij, kot je G551D.
A third study involved dogs infested with sarcoptic mange.
Tretja študija je vključevala pse z garjami vrste Sarcoptes.
A third study looked at around 1,000 patients with lung cancer who had had at least one previous chemotherapy treatment and whose tumours produced PD-L1.
V tretji študiji so proučevali približno 1 000 bolnikov s pljučnim rakom, ki so bili predhodno zdravljeni z vsaj eno kemoterapijo in njihovi tumorji proizvajajo beljakovino PD-L1.
A third study, in 578 patients whose disease had not responded or had come back after previous treatment, compared adding Imbruvica or placebo (a dummy treatment) to the cancer medicines bendamustine and rituximab.
578 bolnikov, katerih bolezen se ni odzvala na zdravljenje ali se je ponovila po predhodnem zdravljenju, so primerjali dodajanje zdravila Imbruvica ali placeba (zdravila brez zdravilne učinkovine) k drugima zdraviloma za zdravljenje raka, bendamustinu in rituksimabu.
A third study, using a vaccine with strain A/turkey/Turkey/1/05 (H5N1)-like strain (NIBRG-23), has been carried out in 343 adults aged below and above 60 years.
Tretjo študijo so izvedli pri 343 odraslih, mlajših ali starejših od 60 let, s cepivom, ki je vsebovalo sevu A/turkey/Turkey/1/05 (H5N1) podoben sev (NIBRG-23).
A thorough QT study showed that there was no intrinsic effect of degarelix on QT/QTc interval (see section 4.8).
Temeljita študija intervala QT je pokazala, da degareliks ni imel intrinzičnih učinkov na interval QT/QTc (glejte poglavje 4.8).
A three-arm randomised study investigating the combination of everolimus with exemestane versus everolimus alone versus capecitabine in patients with oestrogen-receptor positive metastatic breast cancer after recurrence or progression on letrozole or anastrozole based on a CHMP approved protocol.
Randomizirana študija s tremi skupnami za primerjavo kombinacije everolimusa z eksemestanom, samega everolimusa in kapecitabina pri bolnicah z metastatskim rakom dojke, pozitivnim na estrogenske receptorje, po ponovitvi ali napredovanju bolezni ob zdravljenju z letrozolom ali anastrozolom po protokolu, ki ga je odobril odbor CHMP.
A timed walking test, e.g. the Timed 25 Foot Walk (T25FW), is recommended to evaluate improvement after two weeks.
Za ovrednotenje izboljšanja po dveh tednih se priporoča preizkus hoje z omejitvijo časa, npr. časovno omejena hoja na 25 čevljev (= 7,62 m) (T25FW – Timed 25 Foot Walk).
a tingling sensation or numbness in the hands, feet or around the lips and mouth
mravljinčenje ali omrtvelost v rokah, stopalih ali okrog ustnic in ust,
A tingling, burning or pricking sensation or numbness of the skin (paresthesia)
občutek mravljinčenja, zbadanja, skelenja ali odrevenelost kože (parestezija)
A tiny drop of liquid will appear at the tip of the needle.
Na konici igle se mora prikazati majhna kaplja tekočine
A titration pack composed of four triple packs is available for the titration period and the patient’s initial treatment with Betaferon.
Set za titriranje je sestavljen iz štirih tridelnih pakiranj, ki so namenjena za obdobje titriranja in začetno zdravljenje bolnikov z zdravilom Betaferon.
a To calculate the volume of injection (mL) for patients < 60 kg, use the following formula: body weight (kg) x 0.0083 (mL/kg) or see Table 2.
a Za izračun volumna raztopine (ml) pri bolnikih s telesno maso < 60 kg uporabite naslednjo formulo: telesna masa (kg) x 0,0083 (ml/kg) ali glejte preglednico 2.
a To report analysis of primary endpoint (Ctrough non-inferiority) for Part 2 and available safety and immunogenicity data from both parts of the ongoing study.
a Poročati o analizi primarnega opazovanega dogodka (Ctrough neinferiorna) za 2. del in razpoložljivih podatkov o varnosti in imunogenosti iz obeh delov študije v teku.
A total of
Skupno
A total of 1,006 patients with KPS≥60 were randomized to the following treatment groups:
V spodnje skupine zdravljenja so naključno razvrstili skupno 1006 bolnikov z zmogljivostjo po Karnofskem ≥ 60:
A total of 1,106 patients were randomised, 553 to each arm.
Randomiziranih je bilo skupno 1.106 bolnikov, 553 na vsak krak.
A total of 1,188 patients with relapsing remitting MS (RRMS) treated with LEMTRADA (12 mg or 24 mg) constituted the safety population in a pooled analysis of controlled clinical studies resulting in 2,363 patient- years of safety follow-up and a median follow-up of 24 months.
Populacijo za oceno varnosti je v združeni analizi kontroliranih kliničnih študij sestavljalo 1.188 bolnikov z recidivno remitentno multiplo sklerozo (RRMS), ki so bili zdravljeni z zdravilom LEMTRADA (12 mg ali 24 mg), kar pomeni 2.363 bolnik-let sledenja varnosti in mediano sledenja 24 mesecev.
A total of 1,620 babies took part in this study.
V študijo je bilo vključenih 1 620 dojenčkov.
A total of 1,871 of these patients had images considered valid for the primary efficacy evaluation, including 1,294 (69%) men and 577 (31%) women with a median age of 66 years (range 26-93 years of age).
Pri skupno 1.871 od teh bolnikov so bili posnetki ocenjeni kot veljavni za ocenitev primarne učinkovitosti, vključno s 1.294 (69%) moških in 577 (31%) žensk z mediano starostjo 66 let (razpon starosti 26–93 let).
A total of 1.106 patients were randomised, 553 to each arm.
Randomiziranih je bilo skupno 1.106 bolnikov, 553 na vsak krak.
A total of 1.25x1011 bacteria of the following strains:
skupaj 1,25 x 1011 bakterij naslednjih sevov:
A total of 1.25x1011 bacteria of the following strains:
skupaj 1.25x1011 bakterij naslednjih sevov:
A total of 10 mg of Votubia dispersible tablets per glass must not be exceeded.
Skupnega dovoljenega odmerka disperzibilnih tablet Votubia 10 mg na kozarec se ne sme prekoračiti.
A total of 10 mg of Votubia dispersible tablets per syringe must not be exceeded.
Skupnega dovoljenega odmerka 10 mg disperzibilnih tablet zdravila Votubia na brizgo se ne sme prekoračiti.
A total of 10 PAH subjects enrolled and completed the study.
V študijo je bilo v celoti vključenih in jo je dokončalo 10 preiskovancev s pljučno arterijsko hipertenzijo.
A total of 10,795 patients were treated in 6 actively controlled VTE prevention trials with at least one dose of the medicinal product.
V šestih aktivno nadzorovanih preskušanjih zdravila pri preprečevanju VTE je sodelovalo 10.795 bolnikov, ki so prejeli najmanj en odmerek zdravila.
A total of 1006 patients with KPS ≥ 60 were randomized to the following treatment groups:
V spodnje skupine zdravljenja je bilo randomiziranih skupno 1006 bolnikov z zmogljivostjo po Karnofskem  60:
A total of 1006 patients with KPS  60 were randomized to the following treatment groups:
V spodnje skupine zdravljenja je bilo randomiziranih skupno 1006 bolnikov z zmogljivostjo po Karnofskem  60:
A total of 1006 patients with KPS≥60 were randomized to the following treatment groups:
V spodnje skupine zdravljenja je bilo randomiziranih skupno 1006 bolnikov z zmogljivostjo po Karnofskem ≥ 60:
A total of 102 severe familial hypercholesterolaemia patients and 96 homozygous familial hypercholesterolaemia patients enrolled in TAUSSIG.
V študijo TAUSSIG sta vključena 102 bolnika s hudo družinsko hiperholesterolemijo in 96 bolnikov s homozigotno družinsko hiperholesterolemijo.
A total of 104 patients were randomised to treatment in this trial, 53 to Avastin 10 mg/kg every 2 weeks plus placebo and 51 to Avastin 10 mg/kg every 2 weeks plus erlotinib 150 mg daily.
Skupno so v zdravljenje v tem preskušanju randomizirali 104 bolnike; 53 v skupino, ki je prejemala zdravilo Avastin 10 mg/kg vsake 2 tedna in placebo, ter 51 v skupino, ki je prejemala zdravilo Avastin 10 mg/kg vsake 2 tedna in 150 mg erlotiniba na dan.
A total of 106 out of 234 (45 %) subjects were evaluable for CPET, which comprised those children ≥ 7 years old and developmentally able to perform the test.
CPET je bilo mogoče ovrednotiti pri skupno 106 izmed 234 (45 %) preiskovancev, v tem številu pa so bili zajeti otroci, stari  7 let, ki so bili glede na stopnjo razvoja sposobni opraviti preskus.
A total of 11 of 31 (36%) patients in the weekly treatment group versus 5 of 31 (16%) patients in the placebo group had an increase in FEV1 of at least 0.02 l at or before the end of the study, indicating a dose-related improvement in airway obstruction.
V skupini, ki je zdravljenje prejemala enkrat tedensko, so pri skupno 11 od 31 (36 %) bolnikov, v skupini, ki je prejemala placebo, pa pri skupno 5 od 31 (16%) na koncu študije ali pred njim opazili povečanje vrednosti FEV1 za najmanj 0,02 l, kar kaže na od odmerka odvisno izboljšanje obstrukcije dihalnih poti.